Leucid Bio appoints Filippo Petti as CEO

18 July 2023

UK-based CAR-T therapies specialist Leucid Bio today announced the appointment of Filippo Petti as its chief executive (CEO), with immediate effect. Mr Petti has also been named as a member of Leucid Bio’s board of directors.

Mr Petti brings broad industry expertise to the organization across operations, finance and research. He has experience working with biotech companies focused on oncology drug development both in the USA. and Europe. Most recently, Mr Petti was CEO and chief financial officer of Celyad Oncology, also a biotechnology company focused on CAR-T cell therapies for cancer.

Prior to Celyad, Mr Petti spent several years as a healthcare investment banker at Wells Fargo Securities and William Blair & Company, where he specialised in working with cell and gene therapy companies. In addition, Mr Petti has worked in equity research both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. before transitioning to corporate development with the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK